Patents by Inventor Keiro Shirotani

Keiro Shirotani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10352927
    Abstract: It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: July 16, 2019
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hisashi Narimatsu, Atsushi Kuno, Yuzuru Ikehara, Yasuhiro Hashimoto, Keiro Shirotani, Kiyomitsu Nara, Yoshinobu Kariya, Hiromi Ito, Kyoka Hoshi
  • Patent number: 10156576
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: December 18, 2018
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Patent number: 9980937
    Abstract: The present invention aims to provide a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease, which has a novel action mechanism and shows less side effects. A polyphenol derivative having liposolubility enhanced by the introduction of at least one kind of a liposoluble group selected from the group consisting of a chain saturated hydrocarbon group, a chain unsaturated hydrocarbon group, a cyclic saturated hydrocarbon group, a cyclic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a liposoluble vitamin residue and a sterol residue has an action to potentiate neprilysin activity, and is useful as a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 29, 2018
    Assignee: NAGASAKI UNIVERSITY
    Inventors: Nobuhisa Iwata, Keiro Shirotani, Masashi Asai, Takashi Tanaka
  • Publication number: 20170252318
    Abstract: The present invention aims to provide a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease, which has a novel action mechanism and shows less side effects. A polyphenol derivative having liposolubility enhanced by the introduction of at least one kind of a liposoluble group selected from the group consisting of a chain saturated hydrocarbon group, a chain unsaturated hydrocarbon group, a cyclic saturated hydrocarbon group, a cyclic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a liposoluble vitamin residue and a sterol residue has an action to potentiate neprilysin activity, and is useful as a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 7, 2017
    Applicant: NAGASAKI UNIVERSITY
    Inventors: Nobuhisa IWATA, Keiro SHIROTANI, Masashi ASAI, Takashi TANAKA
  • Publication number: 20160187356
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Application
    Filed: March 16, 2016
    Publication date: June 30, 2016
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Publication number: 20150338396
    Abstract: It is intended to develop and provide a method for detecting a particular glycan-isoform rapidly and specifically by a small number of steps. The present invention provides a glycan-isoform detection method comprising quantifying an immune complex formed by the mixing of a test sample with a sugar chain non-reducing terminal residue-binding lectin and an antibody specifically binding to the protein moiety of the glycan-isoform, etc., comparing the obtained amount of the immune complex with the amount of a control immune complex obtained when a control sample is not mixed with the sugar chain non-reducing terminal residue-binding lectin or is mixed with a control protein, and determining the presence or absence of the glycan-isoform of interest in the test sample on the basis of the difference between these amounts.
    Type: Application
    Filed: August 9, 2013
    Publication date: November 26, 2015
    Inventors: Hisashi NARIMATSU, Atsushi KUNO, Yuzuru IKEHARA, Yasuhiro HASHIMOTO, Keiro SHIROTANI, Kiyomitsu NARA, Yoshinobu KARIYA, Hiromi ITO, Kyoka HOSHI
  • Publication number: 20140323324
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 30, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara